Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.53 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.53 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.53 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30038307 | 1.00 | TSHR (0.53) | TSHRALDH1A1CYP3A4TDP1HPGD | |
| SCHEMBL16174996 | 0.89 | TSHR (0.60) | TSHRALDH1A1CYP3A4TDP1HPGD | |
| SCHEMBL3325206 | 0.87 | ALDH1A1 (0.52) | TSHRALDH1A1CYP3A4TDP1HPGD | |
| SCHEMBL31346023 | 0.82 | TDP1 (0.53) | TSHRALDH1A1CYP3A4TDP1HPGD | |
| SCHEMBL5872583 | 0.77 | ALDH1A1 (0.72) | TSHRALDH1A1TDP1HPGDHIF1A | |
| SCHEMBL23302367 | 0.77 | ALDH1A1 (0.48) | TSHRALDH1A1CYP3A4TDP1HPGD | |
| SCHEMBL29896834 | 0.77 | ALDH1A1 (0.48) | TSHRALDH1A1CYP3A4TDP1HPGD | |
| SCHEMBL31495114 | 0.77 | TDP1 (0.47) | TSHRALDH1A1CYP3A4TDP1HPGD | |
| SCHEMBL29805021 | 0.75 | CYP3A4 (0.68) | TSHRALDH1A1CYP3A4TDP1HPGD | |
| SCHEMBL1531127 | 0.75 | CYP3A4 (0.68) | TSHRALDH1A1CYP3A4TDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025037871-A1 | TRICYCLIC COMPOUND AND USE THEREOF AS MAT2A INHIBITOR | 에스케이바이오팜 주식회사 | 2025-02-20 | — | — | WO | disclosed |
| US-20240262842-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME LLC | 2024-08-08 | — | — | US | disclosed |
| US-20240246968-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME LLC | 2024-07-25 | — | — | US | disclosed |
| EP-4329749-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4329750-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230023023-A1 | 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF | ASTEX THERAPEUTICS LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| CN-115551500-A | 4-aminobut-2-enamide derivatives and salts thereof | 大鹏药品工业株式会社 | 2022-12-30 | — | — | CN | disclosed |
| WO-2022232318-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022232320-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-11-03 | — | — | WO | disclosed |
| EP-4051266-A1 | 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021085653-A1 | 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021084765-A1 | 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF | TAIHO PHARMACEUTICAL CO., LTD (JP) | 2021-05-06 | — | — | WO | disclosed |
| WO-2010138833-A1 | SUBSTITUTED IMIDAZO[1,5-a]QUINOXALINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | WYETH (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010054260-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BIOTIE THERAPIES GMBH (DE) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023023-A1 | 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF | KRAS, NRAS, HRAS | TSHR 4626/4885ALDH1A1 2807/4885CYP3A4 4631/4885 |
| US-20240246968-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | KRAS, NRAS, HRAS | TSHR 4468/4885ALDH1A1 3065/4885CYP3A4 4717/4885 |
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | PDE2A, PDE5A, PDE3A | TSHR 2025/4885ALDH1A1 133/4885CYP3A4 219/4885 |
| US-20240262842-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | KRAS, NRAS, HRAS | TSHR 4548/4885ALDH1A1 1875/4885CYP3A4 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.